Ketonal Uno is relevant in therapeutic contexts where supportive symptom management is appropriate, primarily targeting symptoms related to inflammatory or irritative states. This medicine is commonly used across conditions presenting with systemic or localized discomfort, such as chronic rheumatic diseases including rheumatoid arthritis and osteoarthritis. It is also applied in addressing acute pain in musculoskeletal injuries, localized inflammations like tendinitis, and the discomfort of primary dysmenorrhea (menstrual pain).

Quick Fact: Relief for Joint Pain and Swelling

The extended-release formulation may help maintain a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases. This use is applied in addressing symptoms that create noticeable physiological strain, which may assist with maintaining functional stability when symptoms interfere with routine activities. The medication is relevant in conditions characterized by episodic or fluctuating manifestations, and may help maintain a sense of stability when symptoms are more noticeable. It contributes to improved comfort during periods of heightened symptoms, easing the overall symptom load during acute episodes or in post-surgical recovery.

Regulatory References

1. DailyMed information for Ketoprofen Extended-Release Capsules

Ketonal Uno (ketoprofen) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the symptomatic treatment of various pain conditions, including those associated with rheumatoid arthritis, osteoarthritis, dysmenorrhea (menstrual pain), and mild to moderate acute pain, such as headache or toothache.

Contraindications

Certain individuals must not use Ketonal Uno due to potential serious health risks.

Condition	Reason for Contraindication
Allergy to Ketoprofen/NSAIDs	History of asthma, hives (urticaria), or other allergic reactions triggered by aspirin or other NSAIDs.
Active GI Disease	Active or recurrent gastrointestinal (GI) bleeding, ulceration, or perforation. NSAIDs increase the risk of serious GI events.
Severe Organ Failure	Severe, uncontrolled heart failure, or severe liver or kidney impairment.
Coronary Artery Bypass Graft (CABG)	Peri-operative pain treatment for CABG surgery, due to increased risk of heart attack and stroke.
Late Pregnancy	During the third trimester of pregnancy, as it can harm the fetus and cause premature closure of the ductus arteriosus.

Other Precautions

Patients with a history of high blood pressure, mild to moderate heart failure, a recent heart attack or stroke, or risk factors for cardiovascular disease should use this medication with caution and only under medical supervision. It is generally not recommended for use in children and adolescents under 18 years of age.

Interactions with other medicines and products

Ketonal Uno, containing the NSAID Ketoprofen, has officially documented interactions primarily categorized by additive risk (pharmacodynamic) and altered drug exposure (pharmacokinetic).

---

Contraindicated and High-Risk Combinations

Official regulatory information states that Ketoprofen is contraindicated for treating peri-operative pain during Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other NSAIDs is also not generally recommended or should not be co-administered due to a significantly increased risk of serious gastrointestinal adverse events.

---

Pharmacokinetic and Clearance-Altering Interactions

Ketoprofen interacts with several drugs by altering their clearance or its own:

• Probenecid reduces the plasma clearance of Ketoprofen, which can lead to elevated Ketoprofen levels.
• Ketoprofen can cause an elevation of plasma Lithium levels and a reduction in renal Lithium clearance.
• Co-administration with Methotrexate may result in elevated serum levels and increased toxicity of Methotrexate due to effects on its elimination.

---

Pharmacodynamic and Additive Risk

Combinations with the following categories require careful surveillance due to additive risk:

• Anticoagulants (e.g., Warfarin), Antiplatelet Agents, SSRIs, SNRIs, and Oral Corticosteroids all carry an increased risk of bleeding or serious gastrointestinal events.
• Ketoprofen can diminish the natriuretic effect of Diuretics and may also reduce the antihypertensive effect of ACE Inhibitors.

---

Substance and Food Interactions

Co-ingestion of alcohol is officially documented to increase the risk of stomach bleeding. Similarly, tobacco smoking enhances the risk of gastrointestinal side effects. For the extended-release capsule, a high-fat meal can cause a delay of about 2 hours in reaching maximum plasma concentration (C max).

The mechanism of action for Ketonal Uno is defined by the precise molecular intervention of its active ingredient, Ketoprofen, within the body's key inflammation and pain pathways.

---

Molecular Blockade of Cyclooxygenase (COX) Enzymes

This domain addresses the drug's fundamental biological targets and interaction type. Ketoprofen engages in non-selective competitive reversible inhibition of the COX-1 and COX-2 enzymes. This molecular blockade is the initial step, initiating the primary mechanistic process by blocking the access of arachidonic acid to the enzyme site.

---

⬇️ Suppression of Prostaglandin Synthesis and Signaling

This domain covers the crucial pathway disruption and resulting physiological consequence. By inhibiting COX, the drug rapidly suppresses the synthesis of prostaglandins, especially PGE2, which are central mediators that both intensify signals at peripheral nerve endings and modulate the localized processes of inflammation. This mechanism results in reduced inflammatory responses and decreased peripheral nociceptor sensitization.

---

️ Modulation of the Hypothalamic Thermostat

This distinct central domain explains the mechanism of the antipyretic effect. The drug's active molecule crosses into the CNS to suppress PGE2 production specifically within the hypothalamus. This molecular action directly resets the elevated thermal set point, initiating physiological mechanisms for heat dissipation and resulting in temperature normalization.

How to Use Ketonal Uno

Ketonal Uno is administered through the oral route as a 150 mg extended-release capsule. The use of this medicine is based on established administration protocols.

---

Administration Protocol

Feature	Instruction
Route of administration	Oral route only
Standard Dosing Regimen	150 mg (one capsule)
Dosing Frequency	Once daily (single administration)
Intake Condition	Must be taken with or after food or milk

The 150 mg dose is the standard regimen for the extended-release form. The once-daily frequency is integral to the product's design, which provides sustained release of the active ingredient, Ketoprofen. This daily pattern of use is maintained throughout the required duration of treatment.

Special Administration Requirements

To preserve the long-acting action of the medicine, the extended-release capsule must be swallowed whole and intact; it must not be chewed, crushed, or divided. Taking the capsule with food or milk is part of the administration procedure and helps minimize local gastrointestinal effects. In the event of a missed dose, the instruction is to not double the next dose to compensate, but instead to take the next scheduled dose as planned.

Population-Specific Use

Dose adjustments are often necessary for certain patient groups. For older adults, the required dose is typically reduced, and the lowest effective dose should be used. Similarly, dose reduction is required for patients with mild-to-moderate renal impairment or hepatic impairment.

Overview of Clinical Research

Ketonal Uno (ketoprofen, extended-release formulation) is an NSAID studied for its ability to influence pain and inflammation. The extended-release formulation is designed to provide a sustained profile of the active substance over time, reducing the peaks and troughs often seen with standard, immediate-release dosage forms.

Evaluation in Chronic Pain Conditions

Research has primarily focused on the drug's role in managing chronic pain associated with musculoskeletal conditions.

• Osteoarthritis and Rheumatoid Arthritis: International prospective studies have investigated the use of extended-release ketoprofen in patients, often those aged 65 years and older, with osteoarthritis and rheumatoid arthritis. These studies monitored changes in patient-reported pain intensity and disease activity over periods, including up to 12 months.
• Key Findings: While treatments were associated with statistically significant improvements in measures like pain at rest and on active motion compared to baseline, no significant differences in efficacy were noted when comparing the extended-release formula directly against standard, immediate-release ketoprofen formulations in some head-to-head trials.

Safety and Tolerability Profile

As with all NSAIDs, clinical trials record side effects. The extended-release formulation is designed to provide a more consistent concentration of the drug, potentially influencing the overall side effect profile.

System Affected	Common Reported Events in Trials
Gastrointestinal	Dyspepsia, nausea, abdominal pain (most frequently reported)
Central Nervous System	Headache, dizziness

Trial data on extended-release formulations indicate that while most side effects were related to the gastrointestinal tract, the events reported were typically not severe. Discontinuation of treatment due to side effects, primarily GI-related, was observed in a fraction of patients, with most discontinuations occurring within the first month of treatment.

Common questions about Ketonal Uno (FAQ)

Q: How is Ketonal Uno different from standard Ketonal tablets?

A: Ketonal Uno is an extended-release formulation of the active ingredient, ketoprofen. According to official product information, this design allows the medicine to release the active substance over a longer period. This formulation has a profile supporting a once-daily administration, distinguishing it from standard, immediate-release tablets which usually require more frequent dosing.

Q: How quickly can I expect Ketonal Uno to start working?

A: Regulatory data for standard forms of ketoprofen indicate that pain relief has been observed within about 30 minutes following a single dose of standard formulations. Because Ketonal Uno is an extended-release medicine, the time it takes for the drug to reach its highest level in the blood may be delayed compared to immediate-release forms.

Q: How long does the pain relief from Ketonal Uno typically last?

A: Official information indicates that the extended-release formulation is designed to provide sustained therapeutic levels of ketoprofen. This sustained profile is consistent with the intended use for sustained symptom management.

Q: How long can a person safely use Ketonal Uno?

A: Official guidance emphasizes that the best way to minimize potential side effects is to use the lowest effective dose for the shortest duration necessary to control symptoms. The decision regarding prolonged use of this medicine is made by a healthcare professional.

Q: What kind of research has been done on Ketonal Uno’s effectiveness?

A: Clinical studies have investigated the drug’s effectiveness in managing the signs and symptoms of rheumatoid arthritis and osteoarthritis. Official product information suggests the extended-release formulation has been associated with improvements in measures of pain intensity in the patient populations studied.

Q: Can people with asthma safely use Ketonal Uno?

A: Official warnings state that this medicine is contraindicated (should not be used) if a person has a history of aspirin-induced asthma or other allergic reactions to NSAIDs. For individuals with pre-existing asthma without that specific sensitivity, official guidance recommends caution and close monitoring.

Q: What kind of pain is Ketonal Uno primarily used for?

A: Regulatory documents indicate that the extended-release capsule is officially indicated for the management of pain and stiffness associated with rheumatoid arthritis and osteoarthritis. These are chronic, inflammatory musculoskeletal conditions.

Q: Why is this drug sometimes called ketoprofen?

A: Ketoprofen is the active substance or generic name of the medicine contained within the product known as Ketonal Uno. This is the name used by regulatory bodies globally to classify the drug molecule and its properties.

Q: Can Ketonal Uno be used for common headaches?

A: While the extended-release capsule is indicated for chronic conditions like rheumatoid arthritis and osteoarthritis, other standard formulations of ketoprofen are officially indicated for the temporary relief of minor aches and pains, which can include headache.

Q: Is Ketonal Uno known to cause stomach upset?

A: Official adverse reaction data includes common reports of dyspepsia (indigestion), nausea, and abdominal pain (incidence greater than 1%). These symptoms are often what patients refer to as 'stomach upset'.

Q: Is it normal to feel a bit dizzy after taking Ketonal Uno?

A: Regulatory documents list dizziness as a common adverse reaction associated with this medicine. It is a known effect that has been reported by more than 1% of patients in clinical trials.

Q: Can I take Ketonal Uno if I am also taking an antidepressant?

A: Ketoprofen can interact with certain types of antidepressants, specifically SSRIs and SNRIs. According to official information, co-administration is associated with an increased risk of bleeding or serious gastrointestinal events.

Q: What are the typical indications for using Ketonal Uno?

A: Official therapeutic indications for this extended-release formulation are the management of the signs and symptoms associated with rheumatoid arthritis and osteoarthritis.

Q: Is Ketonal Uno used for nerve pain?

A: The official indications for this medicine focus on pain and inflammation due to musculoskeletal conditions, such as rheumatoid arthritis. Regulatory documents do not specifically list 'nerve pain' (neuropathic pain) as one of the approved uses.

Q: Does taking Ketonal Uno require any special monitoring?

A: Official guidance indicates that for patients on long-term treatment, monitoring of blood count, as well as liver and kidney function, is recommended. Close monitoring of kidney function is also specifically advised for at-risk patients, such as the elderly.

Q: Is Ketonal Uno known to interact with stomach acid reducers?

A: Regulatory sources generally recommend taking ketoprofen with food or antacids to help minimize potential gastrointestinal distress. Specific interactions with prescription stomach acid reducers are not detailed across all official documents.

Q: Is the slow-release nature of Ketonal Uno linked to fewer side effects?

A: The extended-release design is intended to provide a more consistent concentration of the drug. However, official warnings still highlight that all NSAIDs, including this one, carry the documented Boxed Warning for serious gastrointestinal and cardiovascular risks.

Q: What is the general classification of pain that Ketonal Uno is meant to treat?

A: The pain the extended-release formulation is intended to treat is classified as being associated with chronic, inflammatory musculoskeletal conditions, such as rheumatoid arthritis and osteoarthritis, as defined by official regulatory indications.

Q: Does Ketonal Uno have any impact on the immune system?

A: Official warnings state that this medicine, like other NSAIDs, may potentially mask the symptoms of an underlying infectious disease. This occurs because the drug reduces fever and inflammation, which are key defense mechanisms of the body.

How to Store and Dispose of Ketonal Uno

Ketonal Uno (ketoprofen extended-release capsules) must be stored strictly according to regulatory mandates to preserve its stability and effectiveness.

Storage Category	Official Requirement
Temperature	Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Protection	The medicine must be kept from freezing and protected from light, moisture, and excess heat.
Container	Keep the medicine in the original container, and ensure the container is tightly closed.
Child Safety	The product must be kept out of the sight and reach of children.
Disposal	Unused or expired medication must be discarded according to official local regulations, often through a drug take-back program.

These conditions ensure the physical integrity of the modified-release capsule and are critical for safe household storage.